REFERENCING the potent H7N9 strain of influenza, CSL vaccine offshoot Seqirus has alerted investors to the possibility of another influenza pandemic.
Presenting at the Macquarie Australia Equities Conference in Apr, Seqirus President, Gordon Naylor, said that the world has had four influenza pandemics in the last century.
He stressed that the next pandemic is "a question of 'when' not 'if'".
The previous pandemics cited were Asian Flu (H2N2) in 1957-58, the Hong Kong Flu (H3N2) 1968-69, the Swine Flu (H1 N1) in 2009 and the Spanish Flu (H1N1) last year.
Naylor highlighted the dominant global health burden of influenza, showing a chart that demonstrated influenza has a significantly higher incidence and higher mortality than any other infectious disease.
The ultimate communication message from Naylor's presentation was of course to present the company's progress and future prospects to potential investors.
Seqirus' Flucelvax and Fluad were main growth drivers identified and supported by effectiveness data.
The company is "well-placed to deliver further growth" with its "proprietary marketed technologies of cell-culture and MF59", and commitment "to ongoing innovation to deliver sustainable growth," Naylor said.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 19
